HRP20140646T1 - Postupak sinteze morfolino oligomera - Google Patents

Postupak sinteze morfolino oligomera Download PDF

Info

Publication number
HRP20140646T1
HRP20140646T1 HRP20140646AT HRP20140646T HRP20140646T1 HR P20140646 T1 HRP20140646 T1 HR P20140646T1 HR P20140646A T HRP20140646A T HR P20140646AT HR P20140646 T HRP20140646 T HR P20140646T HR P20140646 T1 HRP20140646 T1 HR P20140646T1
Authority
HR
Croatia
Prior art keywords
morpholino
group
nitrogen
protected
lower alkyl
Prior art date
Application number
HRP20140646AT
Other languages
English (en)
Croatian (hr)
Inventor
Christina Mary Josephine Fox
Matthew Dale Reeves
Dwight D. Weller
Yongfu Li
Original Assignee
Sarepta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics, Inc. filed Critical Sarepta Therapeutics, Inc.
Publication of HRP20140646T1 publication Critical patent/HRP20140646T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HRP20140646AT 2007-11-15 2008-11-14 Postupak sinteze morfolino oligomera HRP20140646T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98820007P 2007-11-15 2007-11-15
US98819207P 2007-11-15 2007-11-15
PCT/US2008/012804 WO2009064471A1 (en) 2007-11-15 2008-11-14 Method of synthesis of morpholino oligomers

Publications (1)

Publication Number Publication Date
HRP20140646T1 true HRP20140646T1 (hr) 2014-09-26

Family

ID=40293764

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140646AT HRP20140646T1 (hr) 2007-11-15 2008-11-14 Postupak sinteze morfolino oligomera

Country Status (13)

Country Link
EP (1) EP2207779B1 (enExample)
JP (3) JP5512533B2 (enExample)
KR (1) KR101617472B1 (enExample)
CN (1) CN101861318A (enExample)
BR (1) BR122019021332A8 (enExample)
CA (2) CA2704261C (enExample)
DK (1) DK2207779T3 (enExample)
ES (1) ES2479393T3 (enExample)
HR (1) HRP20140646T1 (enExample)
IL (1) IL205776A0 (enExample)
MX (1) MX2010004955A (enExample)
RU (1) RU2606627C2 (enExample)
WO (1) WO2009064471A1 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
BR112012011381B8 (pt) 2009-11-13 2021-05-25 Avi Biopharma Inc oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo
KR102095478B1 (ko) 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
HUE030292T2 (en) * 2010-09-30 2017-04-28 Nippon Shinyaku Co Ltd Morpholino-nucleic acid derivatives
EP3067420A1 (en) 2010-11-12 2016-09-14 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
KR102339196B1 (ko) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
AU2012284259A1 (en) 2011-07-15 2014-03-06 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
ES2832531T3 (es) 2011-11-30 2021-06-10 Sarepta Therapeutics Inc Oligonucleótidos para el tratamiento de enfermedades por expansión de repeticiones
US9326992B2 (en) 2011-12-08 2016-05-03 Sarepta Therapeutics, Inc. Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
CN117721110A (zh) 2011-12-28 2024-03-19 日本新药株式会社 反义核酸
CA2868174A1 (en) 2012-03-20 2013-09-26 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
EP2946013A1 (en) 2013-01-16 2015-11-25 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
CN105228999B (zh) 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
TWI736514B (zh) 2013-09-05 2021-08-21 美商薩羅塔治療公司 酸性α葡萄糖苷酶之反義股誘導之外顯子２包含
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
WO2015137409A1 (ja) 2014-03-12 2015-09-17 日本新薬株式会社 アンチセンス核酸
EP3620178A3 (en) 2014-05-16 2020-07-22 Oregon State University Antisense antibacterial compounds and methods
US10391098B2 (en) 2014-05-19 2019-08-27 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
SI3159409T1 (sl) 2014-06-17 2020-02-28 Nippon Shinyaku Co., Ltd. Protismiselna nukleinska kislina za uporabo pri zdravljenju Duchennove mišične distrofije
JP6673211B2 (ja) 2014-10-14 2020-03-25 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
JP6994941B2 (ja) 2014-12-31 2022-02-04 オレゴン ステート ユニバーシティ アンチセンス抗細菌性化合物および方法
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2016187425A1 (en) 2015-05-19 2016-11-24 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
KR20250005537A (ko) * 2015-08-05 2025-01-09 에자이 알앤드디 매니지먼트 가부시키가이샤 균질한 올리고머의 제조를 위한 키랄 시약
CA2995995A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
PL3351633T3 (pl) 2015-09-15 2020-11-02 Nippon Shinyaku Co., Ltd. Antysensowny kwas nukleinowy
WO2017047741A1 (ja) 2015-09-16 2017-03-23 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
CA3006748A1 (en) 2015-12-15 2017-06-22 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
KR102522059B1 (ko) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
SG11201809468XA (en) 2016-04-29 2018-11-29 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
WO2017205879A2 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101836TA (en) 2016-05-24 2021-03-30 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MD3464305T2 (ro) 2016-05-24 2025-01-31 Sarepta Therapeutics Inc Procedee de preparare de oligomeri
KR102504759B1 (ko) 2016-05-24 2023-02-28 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
SG11201809494VA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Pharmaceutical composition comprising eteplirsen
CN116804031A (zh) * 2016-09-20 2023-09-26 科罗拉多州立大学董事会法人团体 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体
DK3554552T3 (da) 2016-12-19 2022-10-24 Sarepta Therapeutics Inc Exon-skipping-oligomerkonjugater mod muskeldystrofi
MD3554553T2 (ro) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
MA65895B1 (fr) 2016-12-19 2024-06-28 Sarepta Therapeutics, Inc. Conjugués d'oligomères induisant le saut d'exons pour la dystrophie musculaire
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA49986A (fr) * 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
JP7394753B2 (ja) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド アンチセンスオリゴマー化合物
CA3099778A1 (en) 2018-05-10 2019-11-14 Nippon Shinyaku Co., Ltd. Method for preparing oligonucleic acid compound
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
PE20210630A1 (es) 2018-06-26 2021-03-23 Nippon Shinyaku Co Ltd Composicion que comprende el oligonucleotido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne
TW202449155A (zh) 2018-07-27 2024-12-16 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
JP7658900B2 (ja) 2018-12-13 2025-04-08 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
KR20220098217A (ko) 2019-11-13 2022-07-11 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
WO2021095875A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 オリゴ核酸化合物の製造方法
BR112022012114A2 (pt) 2019-12-19 2022-09-06 Nippon Shinyaku Co Ltd Ácido nucleico antissenso que permite o salto de éxons
TWI874546B (zh) 2019-12-26 2025-03-01 日商日本新藥股份有限公司 誘導外顯子５０的跳讀的反義核酸
AU2021226089A1 (en) 2020-02-28 2022-09-15 National Center Of Neurology And Psychiatry Antisense nucleic acid inducing skipping of exon 51
WO2022006871A1 (en) * 2020-07-10 2022-01-13 Changzhou Syntheall Pharmaceuticals Co., Ltd. Processes for preparing oligonucleotides
US20240254158A1 (en) 2021-04-28 2024-08-01 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
US20240287511A1 (en) 2021-05-13 2024-08-29 National University Corporation Chiba University Antisense Oligomer
AU2022279820A1 (en) 2021-05-28 2023-12-14 Sumitomo Pharma Co., Ltd. Antisense nucleic acid
KR20240024176A (ko) 2021-06-23 2024-02-23 니뽄 신야쿠 가부시키가이샤 안티센스 올리고머의 조합
AU2022306542A1 (en) 2021-07-08 2024-01-18 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
WO2023282345A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 腎毒性軽減剤
CN118201606A (zh) 2021-07-08 2024-06-14 日本新药株式会社 肾毒性减轻剂
EP4389893A4 (en) 2021-08-21 2025-09-10 Takeda Pharmaceuticals Co PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR
WO2023034515A2 (en) 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
US20240425864A1 (en) 2021-09-30 2024-12-26 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
JP2024539223A (ja) 2021-10-22 2024-10-28 サレプタ セラピューティクス， インコーポレイテッド 末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー
EP4458833A1 (en) 2021-12-27 2024-11-06 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
JP2025508514A (ja) * 2022-03-01 2025-03-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビス保護活性化グアニンモノマー
JP2025533454A (ja) 2022-09-21 2025-10-07 サレプタ セラピューティクス， インコーポレイテッド Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
AR132529A1 (es) 2023-04-27 2025-07-16 Sarepta Therapeutics Inc Oligómeros antisentido para el tratamiento de la enfermedad renal crónica
US20250171776A1 (en) 2023-08-02 2025-05-29 Sarepta Therapeutics, Inc. Non-canonical cell-penetrating peptides for antisense oligomer delivery
WO2025085810A2 (en) 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
CN117586307B (zh) * 2024-01-19 2024-04-16 凯莱英生命科学技术(天津)有限公司 Pmo鸟苷单体的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577464A5 (enExample) * 1972-09-22 1976-07-15 Ciba Geigy Ag
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0506830B1 (en) * 1989-12-20 2005-12-14 Avi Biopharma, Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US7790694B2 (en) 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
PL2735568T3 (pl) * 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami

Also Published As

Publication number Publication date
WO2009064471A1 (en) 2009-05-22
BR122019021332A2 (enExample) 2015-05-26
KR20100090681A (ko) 2010-08-16
ES2479393T3 (es) 2014-07-24
JP5512533B2 (ja) 2014-06-04
BR122019021332A8 (pt) 2022-12-06
DK2207779T3 (da) 2014-07-14
CA2884340A1 (en) 2009-05-22
CN101861318A (zh) 2010-10-13
EP2207779A1 (en) 2010-07-21
AU2008321409B2 (en) 2014-08-14
AU2008321409A1 (en) 2009-05-22
JP2014159432A (ja) 2014-09-04
JP6178744B2 (ja) 2017-08-09
JP2016196494A (ja) 2016-11-24
IL205776A0 (en) 2010-11-30
RU2010123958A (ru) 2011-12-20
BRPI0819828A8 (pt) 2022-12-27
JP2011503184A (ja) 2011-01-27
HK1144424A1 (en) 2011-02-18
EP2207779B1 (en) 2014-04-09
KR101617472B1 (ko) 2016-05-02
CA2884340C (en) 2017-07-25
CA2704261A1 (en) 2009-05-22
CA2704261C (en) 2015-05-26
BRPI0819828A2 (pt) 2015-05-26
RU2606627C2 (ru) 2017-01-10
MX2010004955A (es) 2010-06-30

Similar Documents

Publication Publication Date Title
HRP20140646T1 (hr) Postupak sinteze morfolino oligomera
JP2011503184A5 (enExample)
KR102504759B1 (ko) 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
Bräse The virtue of the multifunctional triazene linkers in the efficient solid-phase synthesis of heterocycle libraries
WO2005097713A1 (en) Fluoridation method
Kuhnast et al. Design and synthesis of a new [18F] fluoropyridine-based haloacetamide reagent for the labeling of oligonucleotides: 2-bromo-N-[3-(2-[18F] fluoropyridin-3-yloxy) propyl] acetamide
CN102007091A (zh) 用于直接亲核步骤的纯化策略
PH12015501004B1 (en) AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHa RESPONSES
Thompson et al. Double-sided α-helix mimetics
Podolan et al. Studies on the Synthesis of Specifically Fluorinated 4‐Amino‐pyridine Derivatives by Regioselective Nucleophilic Aromatic Substitution and Catalytic Hydrodefluorination
AU2017270975A1 (en) Processes for preparing phosphorodiamidate morpholino oligomers
KR20110098812A (ko) 양전자 방출 동위원소로 표지화하기 위한 트리아릴-술포늄 화합물, 키트 및 방법
WO2017205496A1 (en) Processes for preparing oligomers
Pretze et al. Automated preparation of [18F] AFP and [18F] BFP: Two novel bifunctional 18F-labeling building blocks for Huisgen-click
KR102523522B1 (ko) 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
BR112018074330B1 (pt) Processo para preparar um composto oligomérico e compostos oligômeros morfolino fosforodiamidato
JP7022078B2 (ja) ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
HUE032407T2 (en) Plasma catalyzed coupling of pyrazolamides
Xu et al. Polymer supported bases in solution-phase synthesis. 2. A convenient method for N-alkylation reactions of weakly acidic heterocycles
Cotton et al. Development of a safe process for manufacturing of the potent anticancer agent melflufen hydrochloride
KR20140063577A (ko) Pet 영상화를 위한 18f-플루오로메톡시 화합물의 직접 합성 및 o-([18f]플루오로메틸) 티로신의 보호된 유도체의 직접 방사성합성을 위한 신규 전구체의 제공
KR102761624B1 (ko) 용액공정상 pna 올리고머의 제조방법
JP2008500283A (ja) 精製法
Koyama et al. Highly efficient syntheses of [methyl-11 C] thymidine and its analogue 4′-[methyl-11 C] thiothymidine as nucleoside PET probes for cancer cell proliferation by Pd 0-mediated rapid C-[11 C] methylation
Lizarzaburu et al. Convenient preparation of aryl ether derivatives using a sequence of functionalized polymers